CAMBRIDGE, Mass., Sept. 29, 2017 – Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced that Devyn Smith, Ph.D., Sigilon Therapeutics Chief Strategy Officer and Head of Operations, will present an overview of the company’s development programs at the Cell & Gene Meeting on the Mesa to be held Oct. 4-6, 2017, in La Jolla, California. Presentation details are as follows:
Date: Thursday, Oct. 5, 2017
Time: 1:15 p.m. PDT
Location: Estancia La Jolla Hotel & Spa, La Jolla, California
About Sigilon Therapeutics
Sigilon Therapeutics is developing treatments for chronic diseases using new biomaterials developed at the Massachusetts Institute of Technology that can shield implanted cells from immune attack. Treatments based on Sigilon Therapeutics’ technology platform include cell implants that act as “protein factories” and responsive “living therapeutics,” providing more natural control for diseases that are currently treated with intermittent injection or infusion. Initial areas of focus include hematologic, enzyme deficiency, endocrine and metabolic disorders. More natural control would restore health and free patients from the need for therapies that are disruptive to quality of life.